Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
7.38
+0.29 (4.09%)
At close: Feb 26, 2026, 4:00 PM EST
7.39
+0.01 (0.14%)
After-hours: Feb 26, 2026, 6:32 PM EST
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $352.35 million as of February 26, 2026. Its market cap has increased by 231.74% in one year.
Market Cap
352.35M
Enterprise Value
177.10M
1-Year Change
231.74%
Ranking
Category
Stock Price
$7.38
Market Cap Chart
Since August 10, 2021, Climb Bio's market cap has decreased from $403.20M to $352.35M, a decrease of -12.61%. That is a compound annual growth rate of -2.92%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 25, 2026 | 338.51M | 77.25% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | 403.20M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Aclaris Therapeutics | 358.62M |
| Adlai Nortye | 358.30M |
| Foghorn Therapeutics | 339.77M |
| Immuneering | 338.35M |
| Cabaletta Bio | 335.97M |
| Sutro Biopharma | 334.97M |
| Relmada Therapeutics | 333.67M |
| XOMA Royalty | 331.12M |